Mycophenolate mofetil (MMF)
| Drug Category | Drug | IHD Dosing |
Administration Timing Around HD Session |
|---|---|---|---|
| Immunosuppressants | Mycophenolate mofetil (MMF) | 1-1.5g PO Q12H | Administer Anytime During HD |
|
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
|---|---|---|---|---|---|---|---|
| 434 | > 90 | MMF - PO:18h, IV:17h; mycophenolic acid - PO 8-16h, inactive metabolite MPAG (mycophenolic acyl glucuronide) 13-17h | N/A | 82-97 | 3.6 | N/A | No (low flux) |
References:
- DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB00688
- Mycophenolate. In:Lexi-Drugs Online. Hudson (OH): Lexi-Comp, Inc,; [updated 04/23/12; accessed 04/23/12].
- MacPhee I, Spreafico S, Bewick M et al. Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure. Kidney International 2000; 57, 1164-1168.
- Schleibner S, Schneeberger H, Krauss M, Land W. Mycophenolate mofetil in patients with acute renal failure : evidence of metabolite (MPAG) accumulation and removal by dialysis. Annals of Surgery 1996; 9(Suppl 1), S308-S310.